A retrospective patient experience demonstrated plasma cfRNA PD-L1 by RT-PCR was associated with a statistically significant and clinically meaningful improved OS outcomes with ICI-based treatment compared to positive plasma cfRNA PD-L1 patients treated with chemotherapy alone in metastatic NSCLC [19]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.